The Pfizer-BioNTech vaccine has been authorized for people as young as age 16 and is the only one authorized for any youths. Pfizer recently announced that its trial in adolescents ages 12-15 is fully enrolled and it could seek authorization in the first half of this year.
Moderna’s vaccine has been authorized down to age 18, and it is enrolling adolescents ages 12-17 in trials. Janssen is expected to seek emergency use authorization of its vaccine for adults in the next several weeks and could start trials in adolescents about four to six weeks later. AstraZeneca’s Phase 3 trial in U.S. adults is ongoing, and it could start trials in adolescents early this year.
Over the next several months, all four companies are expected to work on planning for trials in younger children, which may involve testing vaccines at lower doses than for adults.
More information and the complete American Academy of Pediatrics article can be found here: https://www.aappublications.org/news/2021/01/27/acip-covid-vaccine-pediatric-trials-012721